NASDAQ:NBIX Neurocrine Biosciences - NBIX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $97.10 +0.69 (+0.72%) (As of 03/29/2023 05:22 PM ET) Add Compare Share Share Today's Range$95.90▼$97.2650-Day Range$94.11▼$111.3652-Week Range$75.25▼$129.29Volume492,666 shsAverage Volume825,924 shsMarket Capitalization$9.38 billionP/E Ratio63.46Dividend YieldN/APrice Target$125.65 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Neurocrine Biosciences MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside29.4% Upside$125.65 Price TargetShort InterestHealthy2.76% of Shares Sold ShortDividend StrengthN/ASustainability-2.61Upright™ Environmental ScoreNews Sentiment1.17Based on 6 Articles This WeekInsider TradingAcquiring Shares$39.03 M Bought Last QuarterProj. Earnings Growth70.76%From $2.77 to $4.73 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.3.24 out of 5 starsMedical Sector15th out of 999 stocksBiological Products, Except Diagnostic Industry3rd out of 166 stocks 4.3 Analyst's Opinion Consensus RatingNeurocrine Biosciences has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 10 buy ratings, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $125.65, Neurocrine Biosciences has a forecasted upside of 29.4% from its current price of $97.10.Amount of Analyst CoverageNeurocrine Biosciences has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.76% of the outstanding shares of Neurocrine Biosciences have been sold short.Short Interest Ratio / Days to CoverNeurocrine Biosciences has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Neurocrine Biosciences has recently increased by 5.12%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNeurocrine Biosciences does not currently pay a dividend.Dividend GrowthNeurocrine Biosciences does not have a long track record of dividend growth. Previous Next 2.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreNeurocrine Biosciences has received a 24.32% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Valbenazine", "Elagolix", and "Opicapone" products. See details.Environmental SustainabilityThe Environmental Impact score for Neurocrine Biosciences is -2.61. Previous Next 4.0 News and Social Media Coverage News SentimentNeurocrine Biosciences has a news sentiment score of 1.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Neurocrine Biosciences this week, compared to 4 articles on an average week.Search Interest23 people have searched for NBIX on MarketBeat in the last 30 days. This is an increase of 53% compared to the previous 30 days.MarketBeat Follows5 people have added Neurocrine Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Neurocrine Biosciences insiders have bought 406.47% more of their company's stock than they have sold. Specifically, they have bought $39,032,821.00 in company stock and sold $7,706,823.00 in company stock.Percentage Held by InsidersOnly 4.40% of the stock of Neurocrine Biosciences is held by insiders.Percentage Held by Institutions92.58% of the stock of Neurocrine Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Neurocrine Biosciences are expected to grow by 70.76% in the coming year, from $2.77 to $4.73 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neurocrine Biosciences is 63.46, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 122.95.Price to Earnings Ratio vs. SectorThe P/E ratio of Neurocrine Biosciences is 63.46, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 105.72.Price to Book Value per Share RatioNeurocrine Biosciences has a P/B Ratio of 5.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Neurocrine Biosciences (NASDAQ:NBIX) StockNeurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. It discovers, develops, and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.Read More Receive NBIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address NBIX Stock News HeadlinesMarch 29, 2023 | msn.comTeva in pact with Neurocrine to delay Ingrezza genericsMarch 28, 2023 | markets.businessinsider.comNeurocrine (NBIX) Gets a Hold from SVB SecuritiesMarch 29, 2023 | Weiss Ratings (Ad)Fed's Shocking New Plan to Control Your MoneyThe Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. March 22, 2023 | markets.businessinsider.comCitigroup Sticks to Its Buy Rating for Neurocrine (NBIX)March 21, 2023 | finance.yahoo.comNeurocrine Biosciences to Present at the Stifel 2023 CNS DaysMarch 9, 2023 | finance.yahoo.comNeurocrine Biosciences Presents Data on In Vitro Dissolution Performance of INGREZZA® (valbenazine) Capsule Contents via Soft Foods or Feeding Tube at AMDA - PALTC 2023 Annual ConferenceMarch 8, 2023 | finance.yahoo.comNeurocrine Biosciences to Participate at Investor Conferences in MarchMarch 5, 2023 | finance.yahoo.com‘2023 Rally Was a Bull Trap,’ Says Morgan Stanley. But These Stocks Still Have UpsideMarch 29, 2023 | Weiss Ratings (Ad)Fed's Shocking New Plan to Control Your MoneyThe Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. March 4, 2023 | msn.comEvercore ISI Group Upgrades Neurocrine Biosciences (NBIX)March 3, 2023 | markets.businessinsider.comAnalyst Expectations for Neurocrine Biosciences's FutureMarch 3, 2023 | finance.yahoo.comNeurocrine Biosciences Presents Data on Improvements Over Time with Long-Term Use of INGREZZA® (valbenazine) Capsules in Older and Elderly Patients at the American Association for Geriatric Psychiatry 2023 Annual MeetingMarch 3, 2023 | investing.comNeurocrine Biosciences Presents Data on Improvements Over Time with Long-Term Use of INGREZZA Capsules in Older and Elderly PatientsMarch 1, 2023 | benzinga.comNeurocrine Biosciences Stock (NASDAQ:NBIX), Quotes and News SummaryFebruary 19, 2023 | nasdaq.comFirst Week of NBIX April 21st Options TradingFebruary 14, 2023 | finance.yahoo.comSentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF PeptidesFebruary 9, 2023 | finance.yahoo.comNeurocrine Biosciences Full Year 2022 Earnings: EPS Misses ExpectationsFebruary 8, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Incyte (INCY), Neurocrine (NBIX) and Deciphera Pharmaceuticals (DCPH)February 8, 2023 | finance.yahoo.comInvestors one-year returns in Neurocrine Biosciences (NASDAQ:NBIX) have not grown faster than the company's underlying earnings growthFebruary 7, 2023 | finance.yahoo.comNeurocrine Biosciences to Present at the SVB Securities Global Biopharma ConferenceFebruary 7, 2023 | finance.yahoo.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2022 Earnings Call TranscriptFebruary 6, 2023 | finance.yahoo.comNeurocrine Biosciences (NBIX) Lags Q4 Earnings EstimatesFebruary 6, 2023 | finance.yahoo.comNeurocrine Reports 3,000% Profit Growth, But Shares Unexpectedly TumbleFebruary 6, 2023 | finance.yahoo.comIf You're in Neurocrine Biosciences Consider Getting Out: Here's WhyFebruary 6, 2023 | msn.comNeurocrine Biosciences Non-GAAP EPS of $1.24 misses by $0.20, revenue of $412M beats by $3.04MFebruary 4, 2023 | seekingalpha.comIngrezza's Potential To Dominate The Huntington's Chorea Market: A Boost For Neurocrine InvestorsFebruary 3, 2023 | seekingalpha.comNeurocrine Biosciences Q4 2022 Earnings PreviewSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive NBIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address NBIX Company Calendar Last Earnings2/06/2023Today3/29/2023Next Earnings (Estimated)5/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:NBIX CUSIP64125C10 CIK914475 Webwww.neurocrine.com Phone(858) 617-7600Fax858-617-7602Employees1,200Year FoundedN/APrice Target and Rating Average Stock Price Forecast$125.65 High Stock Price Forecast$150.00 Low Stock Price Forecast$95.00 Forecasted Upside/Downside+30.3%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)$1.53 Trailing P/E Ratio63.01 Forward P/E Ratio34.81 P/E GrowthN/ANet Income$154.50 million Net Margins10.38% Pretax Margin14.37% Return on Equity10.19% Return on Assets7.13% Debt Debt-to-Equity RatioN/A Current Ratio2.70 Quick Ratio2.64 Sales & Book Value Annual Sales$1.49 billion Price / Sales6.26 Cash Flow$1.77 per share Price / Cash Flow54.47 Book Value$17.76 per share Price / Book5.43Miscellaneous Outstanding Shares96,590,000Free Float92,338,000Market Cap$9.31 billion OptionableOptionable Beta0.50 Key ExecutivesKevin Charles GormanChief Executive Officer & DirectorBill WilsonVice President-Information Technology & OperationsMatthew C. AbernethyChief Financial OfficerDimitri E. GrigoriadisChief Research OfficerEiry W. RobertsChief Medical OfficerKey CompetitorsRepligenNASDAQ:RGENExelixisNASDAQ:EXELHalozyme TherapeuticsNASDAQ:HALOQiagenNYSE:QGENBio-TechneNASDAQ:TECHView All CompetitorsInsiders & InstitutionsNeo Ivy Capital ManagementBought 2,502 shares on 3/27/2023Ownership: 0.003%Victory Capital Management Inc.Bought 15,478 shares on 3/10/2023Ownership: 0.117%Voya Investment Management LLCBought 36,761 shares on 2/28/2023Ownership: 0.168%NatixisBought 44,649 shares on 2/24/2023Ownership: 0.046%Neurocrine Biosciences IncBought 4,395,588 shares on 2/23/2023Total: $39.03 M ($8.88/share)View All Insider TransactionsView All Institutional Transactions NBIX Stock - Frequently Asked Questions Should I buy or sell Neurocrine Biosciences stock right now? 15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last twelve months. There are currently 5 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NBIX shares. View NBIX analyst ratings or view top-rated stocks. What is Neurocrine Biosciences' stock price forecast for 2023? 15 brokers have issued 1-year price targets for Neurocrine Biosciences' stock. Their NBIX share price forecasts range from $95.00 to $150.00. On average, they expect the company's stock price to reach $125.65 in the next year. This suggests a possible upside of 30.3% from the stock's current price. View analysts price targets for NBIX or view top-rated stocks among Wall Street analysts. How have NBIX shares performed in 2023? Neurocrine Biosciences' stock was trading at $119.44 at the start of the year. Since then, NBIX stock has decreased by 19.3% and is now trading at $96.41. View the best growth stocks for 2023 here. When is Neurocrine Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023. View our NBIX earnings forecast. How were Neurocrine Biosciences' earnings last quarter? Neurocrine Biosciences, Inc. (NASDAQ:NBIX) issued its quarterly earnings data on Monday, February, 6th. The company reported $1.24 earnings per share for the quarter, topping analysts' consensus estimates of $1.15 by $0.09. The company earned $412 million during the quarter, compared to analyst estimates of $408.96 million. Neurocrine Biosciences had a net margin of 10.38% and a trailing twelve-month return on equity of 10.19%. The firm's revenue for the quarter was up 32.1% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.08) EPS. What ETFs hold Neurocrine Biosciences' stock? ETFs with the largest weight of Neurocrine Biosciences (NASDAQ:NBIX) stock in their portfolio include Psyk Etf (PSYK), iShares Neuroscience and Healthcare ETF (IBRN), First Trust NYSE Arca Biotechnology Index Fund (FBT), Goldman Sachs Future Health Care Equity ETF (GDOC), Invesco Dynamic Biotechnology & Genome ETF (PBE), Invesco S&P MidCap Momentum ETF (XMMO), WisdomTree U.S. Growth & Momentum Fund (WGRO) and Invesco S&P MidCap 400 Pure Growth ETF (RFG). What is Kevin C. Gorman's approval rating as Neurocrine Biosciences' CEO? 11 employees have rated Neurocrine Biosciences Chief Executive Officer Kevin C. Gorman on Glassdoor.com. Kevin C. Gorman has an approval rating of 97% among the company's employees. This puts Kevin C. Gorman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Neurocrine Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Netflix (NFLX), AbbVie (ABBV), Walt Disney (DIS), Tesla (TSLA), Block (SQ) and Salesforce (CRM). What is Neurocrine Biosciences' stock symbol? Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX." Who are Neurocrine Biosciences' major shareholders? Neurocrine Biosciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include JPMorgan Chase & Co. (2.26%), Avidity Partners Management LP (1.85%), Renaissance Technologies LLC (1.68%), Price T Rowe Associates Inc. MD (1.48%), Geode Capital Management LLC (1.44%) and Brown Advisory Inc. (1.10%). Insiders that own company stock include Darin Lippoldt, David W Boyer, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, Neurocrine Biosciences Inc, Richard F Pops, Stephen A Sherwin and William H Rastetter. View institutional ownership trends. How do I buy shares of Neurocrine Biosciences? Shares of NBIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Neurocrine Biosciences' stock price today? One share of NBIX stock can currently be purchased for approximately $96.41. How much money does Neurocrine Biosciences make? Neurocrine Biosciences (NASDAQ:NBIX) has a market capitalization of $9.31 billion and generates $1.49 billion in revenue each year. The company earns $154.50 million in net income (profit) each year or $1.53 on an earnings per share basis. How many employees does Neurocrine Biosciences have? The company employs 1,200 workers across the globe. How can I contact Neurocrine Biosciences? Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The official website for the company is www.neurocrine.com. The company can be reached via phone at (858) 617-7600, via email at ir@neurocrine.com, or via fax at 858-617-7602. This page (NASDAQ:NBIX) was last updated on 3/29/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.